

UCLA

UCLA Previously Published Works

Title

LKB1 and YAP phosphorylation play important roles in Celastrol-induced β -catenin degradation in colorectal cancer

Permalink

<https://escholarship.org/uc/item/6zx0h6rw>

Authors

Wang, Shuren

Ma, Kai

Zhou, Cuiqi

et al.

Publication Date

2019

DOI

10.1177/1758835919843736

Copyright Information

This work is made available under the terms of a Creative Commons Attribution-NonCommercial License, available at <https://creativecommons.org/licenses/by-nc/4.0/>

Peer reviewed

LKB1 and YAP phosphorylation play important roles in Celastrol-induced β -catenin degradation in colorectal cancer

Shuren Wang, Kai Ma, Cuiqi Zhou, Yu Wang, Guanghui Hu, Lechuang Chen, Zhuo Li, Chenfei Hu, Qing Xu, Hongxia Zhu, Mei Liu  and Ningzhi Xu

Abstract: Wnt/ β -catenin and Hippo pathways play essential roles in the tumorigenesis and development of colorectal cancer. We found that Celastrol, isolated from *Tripterygium wilfordii* plant, exerted a significant inhibitory effect on colorectal cancer cell growth *in vitro* and *in vivo*, and further unraveled the molecular mechanisms. Celastrol induced β -catenin degradation through phosphorylation of Yes-associated protein (YAP), a major downstream effector of Hippo pathway, and also Celastrol-induced β -catenin degradation was dependent on liver kinase B1 (LKB1). Celastrol increased the transcriptional activation of LKB1, partially through the heat shock factor 1 (HSF1). Moreover, LKB1 activated AMP-activated protein kinase α (AMPK α) and further phosphorylated YAP, which eventually promoted the degradation of β -catenin. In addition, LKB1 deficiency promoted colorectal cancer cell growth and attenuated the inhibitory effect of Celastrol on colorectal cancer growth both *in vitro* and *in vivo*. Taken together, Celastrol inhibited colorectal cancer cell growth by promoting β -catenin degradation via the HSF1–LKB1–AMPK α –YAP pathway. These results suggested that Celastrol may potentially serve as a future drug for colorectal cancer treatment.

Keywords: β -catenin, Celastrol, colorectal cancer, LKB1, YAP

Received: 28 August 2018; revised manuscript accepted: 18 March 2019.

Introduction

As the most common gastrointestinal (GI) tract cancer worldwide, colorectal cancer (CRC) represents the fifth leading causes of cancer deaths among both men and women.¹ CRC acquires many genetic alterations, and some signaling pathways involved are clearly singled out as key factors in tumor formation. Activation of the Wnt pathway is regarded as the initiating event in CRC.² The core of Wnt signaling is β -catenin, which is regulated by a cytoplasmic destruction complex consisting of a central scaffold protein Axin, adenomatous polyposis coli (APC), glycogen synthase kinase 3 β (GSK-3 β), and casein kinase 1 (CK1).³ As an critical transcriptional co-activator of the Wnt pathway, β -catenin regulates target gene expression.⁴ Aberrant expression of β -catenin induces malignant transformation of normal cells, and its abnormal activity has been reported in many cancer types.

Hippo signaling interacts with Wnt/ β -catenin pathway.⁵ Activation of the Hippo pathway leads to phosphorylation of Yes-Associated Protein (YAP) and transcriptional coactivator with PDZ binding motif (TAZ) [also referred to as WW-domain containing transcriptional regulator 1 (WWTR1)].⁶ Accumulating evidence has strongly suggested the critical role of dysregulated YAP in the tumorigenesis. YAP is required for the development of APC-deficient adenomas.⁷ Hyperactivated YAP results in widespread early onset polyp formation following dextran sulfate sodium (DSS) treatment that induces inflammatory bowel disease.⁸ In addition, YAP promotes the nuclear accumulation of β -catenin in intestinal regeneration and the survival of β -catenin-driven colon cancers.^{9,10} Transgenic expression of YAP reduces Wnt target gene expression and results in the rapid loss of intestinal crypts.¹¹ Previous studies showed that APC (a negative

Ther Adv Med Oncol

2019, Vol. 10: 1–19

DOI: 10.1177/
1758835919843736

© The Author(s), 2019.
Article reuse guidelines:
sagepub.com/journals-
permissions

Correspondences to:

Mei Liu
Laboratory of Cell and
Molecular Biology and
State Key Laboratory
of Molecular Oncology,
National Cancer Center/
National Clinical Research
Center for Cancer/
Cancer Hospital, Chinese
Academy of Medical
Sciences and Peking
Union Medical College,
17 PanjiayuanNanli,
Chaoyang District, P.O.
Box 2258, 100021, Beijing,
P. R. China
liumeif@cicams.ac.cn

Ningzhi Xu
Laboratory of Cell and
Molecular Biology and
State Key Laboratory
of Molecular Oncology,
National Cancer Center/
National Clinical Research
Center for Cancer/
Cancer Hospital, Chinese
Academy of Medical
Sciences and Peking
Union Medical College,
17 PanjiayuanNanli,
Chaoyang District, P.O.
Box 2258, 100021, Beijing,
P. R. China
State Key Laboratory
of Biotherapy and
Cancer Center, West
China Hospital,
Sichuan University, and
Collaborative Innovation
Center for Biotherapy,
No.17, 3rd Section of
People's South Road,
Chengdu, 610041, P.R.
China
xuningzhi@cicams.ac.cn

Shuren Wang
Kai Ma
Yu Wang
Guanghui Hu
Lechuang Chen
Chenfei Hu
Qing Xu
Hongxia Zhu
Laboratory of Cell and
Molecular Biology and
State Key Laboratory
of Molecular Oncology,
National Cancer Center/
National Clinical Research
Center for Cancer/Cancer
Hospital, Chinese Academy

of Medical Sciences and Peking Union Medical College, Beijing, China

Cuiqi Zhou

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Zhuo Li

Department of Pathology, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

regulator of β -catenin) could dually regulate YAP and β -catenin through parallel pathways involving the Hippo kinase cascade and the β -catenin destruction complex, respectively.^{5,7} These observations suggest the important interactions of β -catenin and YAP in CRC.

LKB1/AMPK α pathway is a ubiquitous pathway that controls a wide range of cellular functions including metabolism, proliferation, and cell shape.¹² LKB1 inactivation is frequently observed in a variety of cancers.^{13,14} AMPK α , a LKB1 main downstream target, is an intracellular energy sensor involved in cancer progression.¹⁵ Recent reports showed cross-talk of LKB1/AMPK α pathway and Hippo pathway in the central nervous system,¹² and LKB1-deficient cancers exhibit reduced Hippo kinase activity and enhanced YAP-driven transcription.^{16,17} Furthermore, LKB1 inhibits cell proliferation by suppressing the nuclear translocation of YAP and β -catenin in gastric cancer cells.¹⁸ All these prompted that LKB1/AMPK α pathway and Hippo pathway had inseparable relationships in human cancers.

Celastrol, a triterpene, is a pharmacologically active ingredient initially isolated from the roots of the *Tripterygium wilfordii* plant, which has anti-inflammatory, immune suppression, and antitumor activity.^{19,20} Celastrol induces cell cycle arrest and apoptosis,^{21,22} and acts as inhibitors of heat shock protein 90 (HSP90),²³ nuclear factor (NF)- κ B,²⁴ and proteasome.²⁵ Celastrol activates HSF1 and heat shock response (HSR).^{26,27} HSR is a highly conserved ancient process that helps to maintain protein homeostasis and is essential for cell survival.²⁷ In response to stress, activated HSF1 exerts pleiotropic effects.²⁸ Celastrol ameliorates DSS-induced colitis and ulcerative colitis-related CRC in mice *via* modulating oxidative stress, inflammatory responses, epithelial-mesenchymal transition and intestinal homeostasis.^{29,30} The earliest study showed that β -catenin mediated the apoptosis induction effect of Celastrol in HT29 cells.³¹ Then, Lin *et al.* indicated that Celastrol treatment significantly prevented azoxymethane (AOM)/DSS-induced upregulation of β -catenin expression.³⁰ However, the mechanisms were not well understood.

In the present study, we investigated molecular mechanisms of Celastrol in β -catenin regulation through activating the LKB1-AMPK α pathway and phosphorylating YAP. We also treated C57BL/6J-Apc^{Min/+} (APC^{Min/+}) and AOM-DSS

mouse models with Celastrol, and found that Celastrol exerted a significant inhibitory effect on CRC growth *in vivo*. Our findings indicate the molecular mechanisms underlying Celastrol regulation on β -catenin expression, and shed light on potential application of Celastrol in CRC treatment.

Materials and methods

Cell line, cell culture, and transfections

HEK293, HCT116, and SW480 cell lines were all purchased from the Cell Resource Center (Beijing, China) and identified by short tandem repeat (STR) analysis. T-Rex-293 cell line was presented by Professor Quan Chen (Chinese Academy of Sciences, Beijing, China). The inducible expression system of β -catenin cell line named T-Rex-293/ β -catenin (S37A) was established as described previously.³² HCT116 and SW480 cells were cultured in RPMI 1640 medium (BIOROC) containing 10% fetal bovine serum in a humidified environment at 37°C with 5% CO₂. Cells were transfected in 70–80% confluency using Attractene (Qiagen, Valencia, CA, USA) according to the manufacturer's protocol. Stably transfected cells were selected with 10 μ g/ml puromycin for 14 days.

Reagents and plasmids

Celastrol (purity > 98%) was purchased from Mingrui Inc. (Shanghai, China). Cycloheximide (C4859) was purchased from Sigma-Aldrich (St. Louis, MO, USA). PS-341 (Bortezomib, No. S1013) and Compound C (Dorsomorphin 2HCl, NO.S7306) were purchased from Selleck Chemicals (USA). MDL-28170 and HSF1 siRNAs (sc-35611) were purchased from Santa Cruz (USA). YAP siRNA was purchased from Integrated DNA Technologies (IDT, Coralville, IA, USA). HSF1 expression plasmid (CH864887) was purchased from Vigene Biosciences (Shandong, China). YAP and YAP^{S127A} expression plasmids were constructed as described previously.³³ A DNA fragment covering the LKB1 coding region was synthesized and constructed into pcDNA4/TO/myc-His B (Invitrogen, Carlsbad, CA, USA).

MTT assay

A total of 3000 HCT116 and SW480 cells were seeded into 96-well culture plate per well, and treated with Celastrol (0.75 μ M) for 5 days.

Nontreated cells were used as controls and non-cell wells with medium used as blank. MTT assay was performed as described previously.³⁴

Cell colony formation assay

A total of 800 cells were plated to 6-well plates per well and treated with Celastrol (0.75 μ M). Medium with or without Celastrol (0.75 μ M) was changed every 4 days. After 2 weeks, cells were washed with phosphate-buffered saline (PBS), fixed with formaldehyde, and stained with Giemsa staining solution. Nontreated cells were used as controls. Clones larger than 100 μ m in diameter were counted under an Olympus inverted microscope.

Western blot

Cells were harvested and lysed in RIPA buffer (Cell Signaling Technology). Nuclear and cytoplasmic proteins were separated by NE-PERTM Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher, No. 78833). Western blot analysis was performed with the use of conventional protocols as described previously.³⁵ Primary antibodies used were: β -actin (1:5000, Sigma-Aldrich, A1978), PARP (1:1000, Cell Signaling Technology, No. 9542), YAP (1:1000, Cell Signaling Technology, No. 4912), phospho-YAP(Ser127) (1:1000, Cell Signaling Technology, No. 13008), phospho- β -catenin (Ser33/37/Thr41) (1:1000, Cell Signaling Technology, No. 9561), phospho-GSK-3 β (Ser9) (1:1000, Cell Signaling Technology, No. 9336), HSF1 (1:1000, Cell Signaling Technology, No. 12972), Axin1 (1:1000, Cell Signaling Technology, No. 2087), AMPK α (1:1000, Cell Signaling Technology, No. 5831), phospho-AMPK α (Thr172) (1:1000, Cell Signaling Technology, No. 2535), Ubiquitin (1:1000, Cell Signaling Technology, No. 3936), β -Trop (1:1000, Cell Signaling Technology, No. 4394), β -catenin (1:1000, Santa Cruz, sc-7963), LKB1 (1:1000, Santa Cruz, sc-32245), Lamin B (1:1000, Santa Cruz, sc-6217), c-myc (1:1000, Santa Cruz, sc-789), and Survivin (1:1000, Santa Cruz, sc-10811). Each Western blot was repeated at least three times for reproducibility and the intensities of the bands were analyzed using ImageJ software.

Quantitative real-time polymerase chain reaction (Q-PCR)

Quantitative real-time polymerase chain reaction (Q-PCR) was performed as described previously.³⁴

All the primers used are listed in Supplementary Table 1.

Luciferase reporter assay

TOPFLASH or FOPFLASH reporter and control plasmid pRL-TK were transfected into HEK293 cells, respectively. After transfection for 24 h, cells were treated with or without Celastrol (0.5 μ M) for another 24 h. Luciferase activity was detected using the Dual Luciferase Reporter system (Promega) according to the manufacturer's instructions.

Immunofluorescence

Cells or frozen sections at 5 μ m thickness were fixed in 4% paraformaldehyde and methanol for 20 min at room temperature, respectively. Immunofluorescence was performed as described previously.³³ Antibodies used were including anti- β -catenin (1:1000, BD, 610154), anti-YAP (1:500, Cell Signaling Technology, NO.14074), Dylight 649-goat anti-mouse IgG (1:500, Earth Ox Life Sciences, E032610-01), and Dylight 488-goat anti-rabbit IgG (1:500, EarthOx Life Sciences, E032220-01).

TdT-mediated dUTP nick end labeling assay

Sections at 5 μ m thickness were confirmed with *in situ* cell death detection kit, alkaline phosphatase (Roche Applied Science), in accordance with the manufacturer's instructions. Apoptotic cells (dark blue staining) were counted three times in five random fields of vision under microscope.

Immunoprecipitation assay

Six million cells were lysed using nondenaturing lysis buffer (Pu Lilai Gene Technology, Beijing, China). The cell lysates were incubated with 30 μ l of nonimmune IgG protein G-Sepharose for 1 h at 4°C and then centrifuged. The supernatant was incubated sequentially with 1–2 μ g of appropriated antibodies and 30 μ l of protein G-Sepharose (IgG as control) overnight at 4°C, and washed with nondenaturing lysis buffer for 3 times. Precipitated proteins were identified by Western blot analysis.

Chromatin immunoprecipitation assay

Eight million HCT116 cells were cross-linked and lysed. Chromatin immunoprecipitation (ChIP)

assay was performed as described previously.³³ The primers that used to detect the LKB1 promoter region are listed in Supplementary Table 2. ChIP assay was repeated at least three times and representative results are shown.

Immunohistochemistry

Immunohistochemistry was performed as described previously.³⁶ Primary antibodies were used including anti- β -catenin (1:1000, BD, 610154), anti-HSF1 (1:200, Cell Signaling Technology, No. 12972), anti-LKB1 (1:100, Santa Cruz, sc-32245), and anti-PCNA (1:1000, Santa Cruz, sc-7907).

Tumor xenograft model

Two million cells were suspended in 0.1 ml of saline and injected subcutaneously into 6-week-old female Balb/c nude mice. Four different groups of cells were injected including HCT116, HCT116/LKB1-KO, SW480, and SW480/LKB1-KO, and each group consisted of five animals. Three weeks after tumor cell injection, mice were intraperitoneally injected with Celestrol for 2 weeks (1 mg/kg, three times a week), and sacrificed 1 week after the last Celestrol injection. Tumor xenografts were separated and measured at the end of the experiment.

In vivo experiments

C57BL/6J-APC^{Min/+} male mice were purchased from Jackson Laboratory (Bar Harbor, ME) and then bred with wildtype C57BL/6J female mice to obtain APC^{Min/+} alleles that were identified by PCR assays as described previously.³⁷ Twelve-week-old APC^{Min/+} mice were intraperitoneally injected with Celestrol (1 mg/kg) or PBS as control for 3 weeks (three times/week). Mice were sacrificed at 18 weeks old after treatment.

The AOM/DSS-induced mouse model was established as described previously.³⁸ At the second cycle, mice were intraperitoneally injected with Celestrol (1 mg/kg) or PBS for 3 weeks (three times/week), and sacrificed at 18 weeks old.

LKB1^{loxp/loxp} mice were purchased from Jackson Laboratory (Bar Harbor, ME). *Pvillin-Cre* mice were purchased from Nanjing Biomedical Research Institute of Nanjing University (Nanjing, China). LKB1^{loxp/loxp} mice were crossbred with *Pvillin-Cre* mice to generate intestinal-specific LKB1-KO mice. Genotypes were determined by PCR using

genomic DNA extracted from tails. Both heterozygous deletion (*Cre*⁺ LKB1^{+/loxp}) and homozygous deletion (*Cre*⁺ LKB1^{loxp/loxp}) of LKB1 mice were treated with AOM/DSS and received intraperitoneal injection of Celestrol or PBS as described previously. Mice were sacrificed at 18 weeks old.

All animals were handled in strict accordance with good animal practice as defined by the Beijing Municipal Science and Technology Commission, and all protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of National Cancer Center/Cancer Hospital (Approval No. NCC2015A019).

Statistical analysis

Results were presented as mean \pm standard deviation (SD) or \pm standard error of the mean (SEM). Student's two-tailed nonpaired *t*-test was used to determine significance between treatment and control groups in all experiments. $p < 0.05$ was considered statistically significant.

Results

Celestrol inhibited cell growth and induced cell apoptosis in CRC

To investigate the effect of Celestrol on CRC cell growth, MTT and colony formation assays were performed in SW480 and HCT116 cells. Celestrol significantly inhibited cell growth (up to 60.14% reduction in SW480 and 46.61% reduction in HCT116 cells) and colony formation (up to 64.13% reduction in SW480 and 99.49% reduction in HCT116 cells) at a concentration of 0.75 μ M as compared with nontreated control cells (Figure 1A and B and Supplementary Figure S1A). Furthermore, we used C57BL/6J-Apc^{Min/+} (APC^{Min/+}) and AOM/DSS-treated mice, and intraperitoneally injected Celestrol for 3 weeks (1 mg/kg, 3 times/week) to assess the suppression effect of Celestrol on colorectal tumorigenesis *in vivo*. As shown in Figure 1C and D, in contrast to nontreated mice, Celestrol injection significantly reduced the tumor numbers from 38.6 ± 4.1 ($n = 15$) to 13.1 ± 2.2 ($n = 18$) (mean \pm SEM, $p < 0.0001$) in the small intestine of APC^{Min/+} mice, and decreased the tumor numbers from 12.8 ± 2.3 ($n = 5$) to 4.3 ± 1.0 ($n = 7$) (mean \pm SEM, $p < 0.01$) in the colon of AOM/DSS mice. Notably, Celestrol treatment showed an equivalent efficacy to 5-Fu, which is widely used for CRC treatment (Supplementary Figure S1B and C).




Figure 1. Celastrol inhibited cell growth and induced cell apoptosis in colorectal cancer.

(A) Cell growth curves of Celastrol (0.75 μ M) treated SW480 and HCT116 cells as compared with nontreated controls. Results represent mean \pm standard error of the mean (SEM) ($n = 4$). *** $p < 0.001$.

(B) Colony formation of Celastrol (0.75 μ M, 14 days) treated SW480 and HCT116 cells as compared with nontreated controls. Values are mean \pm SEM ($n = 3$). ** $p < 0.01$, *** $p < 0.001$.

(C) Representative macroscopic images of intestinal tumors in wildtype, APC^{Min/+}, and Celastrol-treated APC^{Min/+} mice. Tumor numbers of colon (middle) and intestine (right) were analyzed. Values are mean \pm SEM. Control mice ($n = 15$), APC^{Min/+} mice ($n = 15$), Celastrol-treated APC^{Min/+} mice ($n = 18$). * $p < 0.05$, *** $p < 0.001$.

Figure 1. (Continued)

Figure 1. (Continued)

(D) Representative macroscopic images of colon tumors in wildtype, AOM/DSS, and Celestrol-treated AOM/DSS mice. Colorectal tumor numbers were analyzed (right). Values are mean \pm SEM. Control wildtype mice ($n = 5$), AOM/DSS mice ($n = 5$), Celestrol-treated AOM/DSS mice ($n = 7$). ** $p < 0.01$.

(E), (F) Immunohistochemistry staining of PCNA in intestinal tissues of APC^{Min/+} mice (E) and colorectal tissues of AOM/DSS mice (F). AD: AOM/DSS mice. Scale bar: 50 μ m (upper), 30 μ m (bottom).

(G) Western blot of cleaved PARP in SW480 and HCT116 cells treated with or without Celestrol (0.75 μ M). β -actin was used as a loading control.

(H), (I) TdT-mediated dUTP nick end labeling (TUNEL) and hematoxylin and eosin (HE) staining of intestinal (H) and colorectal tissues (I). TUNEL-positive (apoptotic) cells were stained blue. AD: AOM/DSS mice. Scale bar: 30 μ m.

Moreover, immunohistochemistry staining results showed that Celestrol treatment decreased proliferating cell nuclear antigen (PCNA) expression in the small intestine of APC^{Min/+} mice (17.1% in Celestrol *versus* 95.2% in controls) and in the colon of AOM/DSS mice (27.6% in Celestrol *versus* 93.0% in controls), as compared with PCNA expression in control mice (Figure 1E and F). In addition to inhibiting proliferation marker PCNA expression, we also detected Celestrol-induced cancer cell apoptosis. Celestrol treatment at 0.75 μ M for 24h enhanced PARP cleavage in SW480 and HCT116 cells (Figure 1G) *in vitro*, and also increased apoptotic cells in intestinal tumors in APC^{Min/+} mice (93.4% in Celestrol *versus* 21.9% in control) and in colorectal tumors in AOM/DSS mice (90.0% in Celestrol *versus* 19.1% in controls) as assessed by TdT-mediated dUTP nick end labeling (TUNEL) assay (Figure 1H and I). These data indicated that Celestrol inhibited intestinal cancer/CRC cell growth by inhibiting proliferation and inducing apoptosis.

Celestrol induced β -catenin degradation through the ubiquitin–proteasome pathway

Dysregulated APC/ β -catenin signaling pathway is an early and common event in CRC, therefore we examined whether Celestrol affects APC/ β -catenin signaling. Western blot results showed that β -catenin abundance were reduced by Celestrol treatment in a dose- and time-dependent manner in both SW480 and HCT116 cells (Figure 2A and Supplementary Figure S2A). Celestrol also significantly decreased β -catenin transcriptional activity (74.2% reduction) as assessed by TOP/FOP luciferase assay (Supplementary Figure S2B). In addition, Celestrol decreased both mRNA and protein levels of β -catenin downstream genes including c-Myc, survivin, CYR61, and Cyclin D1 in SW480 and HCT116 cells (Supplementary Figure S2C and D). Similar results were also observed in mice models. Celestrol treatment reduced β -catenin protein levels in the intestinal mucosa of APC^{Min/+}

mice and the colon of AOM/DSS mice (Figure 2B) as measured by Western blot. Immunohistochemistry staining of β -catenin also showed significantly suppression by Celestrol in these mouse tissues (Figure 2C). Furthermore, Celestrol suppressed the mRNA levels of survivin and c-Jun in intestinal or colorectal tumor tissues of APC^{Min/+} and AOM/DSS mice (Supplementary Figure S2E). Interestingly, expression of constitutively activated β -catenin (β -catenin S37A) rescued the Celestrol-induced PARP cleavage and also promoted cell colony growth as compared with the Celestrol-treated cells without β -catenin S37A transfection, which suggested that sustained activation of β -catenin could attenuate Celestrol-induced cell apoptosis (Supplementary Figure S3A and B).

Different from the change of protein expression, β -catenin mRNA levels were not altered by Celestrol treatment as assessed by Q-PCR, suggesting that β -catenin protein reduction was not due to transcriptional alteration (data not shown). Therefore, we studied Celestrol involvement in β -catenin degradation. SW480 and HCT116 cells were treated with protein synthesis inhibitor cycloheximide (CHX), accompanied with or without Celestrol treatment at 0.75 μ M. CHX treatment alone did not significantly affect β -catenin degradation up to 24h. However, co-incubation of CHX and Celestrol for 12 hours started to significantly decrease β -catenin protein levels in HCT116 and SW480 cells (Figure 2D). These results implied Celestrol involvement in β -catenin protein degradation. Thus we utilized MDL-28170 (a calpain inhibitor III) and PS-341 (a classic proteasome inhibitor) to pre-treat SW480 and HCT116 cells prior to Celestrol treatment. As shown in Figure 2E, PS-341 dramatically blocked Celestrol-triggered β -catenin degradation, but not MDL-28170. In addition, Ub-K48R, which bears a substitution of lysine 48 with arginine and blocks ubiquitin-dependent proteasomal degradation, attenuated β -catenin degradation in HEK293 cells (have wildtype Wnt components) upon Celestrol treatment, compared with wildtype




Figure 2. Celestrol induced β -catenin degradation through the ubiquitin–proteasome pathway.

(A) Western blot of β -catenin in SW480 and HCT116 cells treated with or without Celestrol (0.75 μ M) for 24 h. β -actin was used as a loading control.

(B) β -catenin protein levels in intestinal tissues of APC^{Min/+} mice and colorectal tissues of AOM/DSS mice, with or without Celestrol treatment. β -actin was used as a loading control. N: normal C57 mice; A: APC^{Min/+} mice; AC: APC^{Min/+} mice treated with Celestrol (1 mg/kg); AD: AOM/DSS mice; AD + Cela: AOM/DSS mice treated with Celestrol (1 mg/kg).

Figure 2. (Continued)

Figure 2. (Continued)

(C) Immunohistochemistry staining of β -catenin in intestinal tumor tissues of APC^{Min/+} mice and colon tumor tissues of AOM/DSS mice, treated with or without Celestrol (1 mg/kg), respectively. Wildtype C57 mice were used as a control. AD: AOM/DSS mice. Scale bar: 50 μ m (upper), 30 μ m (bottom).

(D) The effect of cycloheximide (CHX) (10 μ g/ml) alone or in combination with Celestrol (0.75 μ M) on β -catenin expression were evaluated in SW480 and HCT116 cells at indicated time. β -actin was used as a loading control.

(E) The effect of MDL-28170 (50 μ M)/PS-341 (100 nM) alone or in combination with Celestrol (0.75 μ M) on β -catenin expression were evaluated in SW480 and HCT116 cells. β -actin was used as a loading control.

(F) HEK293 cells were transfected with wildtype or mutant (K48R) ubiquitin plasmids for 24 h, and treated with or without Celestrol (0.75 μ M) for another 24 h, respectively. β -catenin were detected and β -actin was used as a loading control.

(G) SW480 and HCT116 cells were treated with or without Celestrol (0.75 μ M) for 24 h. Cell lysates were subjected to immunoprecipitation with β -catenin antibody or protein G-Sepharose (IgG as control), followed by immunoblotting with antibodies against ubiquitin, phospho- β -catenin (Ser33/37/Thr41), β -Trcp, and phospho-GSK-3 β (Ser9). Total lysates were used as input control.

ubiquitin (Figure 2F). As previous studies indicated that β -catenin degradation is initiated by phosphorylation and subsequently by the ubiquitin–proteasome system,³ we immunoprecipitated β -catenin from SW480 and HCT116 cell lysates that were treated with or without Celestrol, β -catenin ubiquitination and phosphorylation were both significantly increased upon Celestrol treatment as shown in Figure 2G. The interaction with β -transducin repeat-containing protein (β -TrCP), a component of a dedicated E3 ubiquitin ligase complex of β -catenin,³ was also increased by Celestrol. Whereas Celestrol decreased the interaction between β -catenin and glycogen synthase kinase-3 β (GSK-3 β) phosphorylation at serine 9 (Figure 2G), which inhibits GSK-3 β activity to phosphorylate β -catenin and present the protein for degradation.³⁹ The above results indicated that Celestrol induced β -catenin degradation through the ubiquitin–proteasome system.

YAP was involved in Celestrol-induced β -catenin degradation

The Hippo pathway genetically and functionally interacts with Wnt/ β -catenin pathway, especially the interaction between YAP and β -catenin.^{5,40} Therefore, we exogenously overexpressed wildtype YAP and mutant YAP^{S127A} in SW480 and HCT116 cells to examine the interaction in CRC cells with Celestrol treatment. As shown in Figure 3A, Celestrol-induced β -catenin decrease could be impaired by overexpression of nuclear-localized YAP^{S127A}, but not wildtype YAP. Surprisingly, Celestrol enhanced YAP phosphorylation at serine 127, which caused subsequent cytoplasmic translocation of YAP and induced YAP degradation (Figure 3A). As shown in Supplementary Figure S3C, the nuclear β -catenin was hardly expressed and overexpression of YAP promoted Celestrol-induced β -catenin degradation in the cytoplasm, which suggested that YAP promoted

cytoplasmic but not nuclear β -catenin degradation. Attenuating YAP by siRNA in SW480 and HCT116 cells led to a remarkable block of β -catenin degradation (Figure 3B), suggesting the indispensability of YAP in β -catenin degradation.

To further study the association of YAP and Axin, we transfected YAP to SW480 and HCT116 cells separately, treated with Celestrol, and carried out immunoprecipitation (IP) of endogenous Axin and β -catenin, respectively, as compared with nontransfected and nontreated control cells. As shown in Figure 3C, YAP was associated with Axin and β -catenin. Exogenous YAP increased β -catenin phosphorylation. Moreover, Celestrol treatment further enhanced the association of YAP and β -catenin and YAP-induced β -catenin phosphorylation (Figure 3D). In contrast, overexpression of a mutant form of YAP (YAP^{S127A}) reduced this association (Figure 3E). Next, we performed immunofluorescent staining to confirm the co-localization of β -catenin and YAP. β -catenin staining was detected predominantly in the nucleus of SW480 cells and in the membrane of HCT116 cells. When treated with Celestrol, the co-localization of β -catenin and YAP became much stronger by sequestering in the cytoplasm in both SW480 and HCT116 cells (Figure 3F). In addition, YAP overexpression promoted Celestrol-induced apoptosis, and mutant YAP^{S127A} overexpression or YAP knock-down restored the effect (Supplementary Figure S3D). Taken together, our data suggested that YAP and its phosphorylation were involved in Celestrol-induced β -catenin degradation.

Celestrol-induced β -catenin degradation and YAP phosphorylation were partly mediated by activating the LKB1–AMPK α pathway via HSF1

Previous data showed that YAP phosphorylation was important in the Celestrol-induced




Figure 3. Yes-associated protein (YAP) was involved in Celastrol-induced β -catenin degradation. (A) SW480 and HCT116 cells were transfected with control plasmid or plasmids expressing wide-type YAP or mutant YAP^{S127A} for 24 h, and treated with or without Celastrol (0.75 μ M) for another 24 h, respectively. β -catenin, YAP, and pho-YAP (S127) were detected and β -actin was used as a loading control. (B) SW480 and HCT116 cells were transfected with scramble or YAP-specific siRNA for 24 h, and treated with or without Celastrol (0.75 μ M) for another 24 h, respectively. β -catenin, YAP, and pho-YAP (S127) were detected. β -actin was used as a loading control. (C) SW480 and HCT116 cells were transfected with control plasmid or YAP-expressing plasmid for 24 h, and treated with or without Celastrol (0.75 μ M) for another 24 h, respectively. Cell lysates were subjected to immunoprecipitation with Axin antibody, followed by immunoblotting with antibodies against Axin, β -catenin, YAP, pho- β -catenin (Ser33/37/Thr41), and pho-YAP (S127) as indicated. Total lysates were used as input control. (D), (E) SW480 and HCT116 cells were transfected with plasmids expressing wildtype YAP or mutant YAP^{S127A} for 24 h, and treated with or without Celastrol (0.75 μ M) for another 24 h, respectively. Cell lysates were subjected to immunoprecipitation with β -catenin antibody, followed by immunoblotting with antibodies against β -catenin and YAP. Total lysates were used as input control. (F) Immunofluorescence of β -catenin and YAP in SW480 and HCT116 cells, treated with or without Celastrol (0.75 μ M) for 24 h. Scale bar: 5 μ m.

β -catenin degradation. LKB1 represses YAP activity *via* promoting YAP phosphorylation, nuclear exclusion, and proteasomal degradation.¹⁵ We found that LKB1 expression was

affected by Celastrol both *in vitro* and *in vivo* (Figure 4A and B), *via* slowing down the degradation process (Supplementary Figure S4A and B). We exogenously overexpressed LKB1 in




Figure 4. Celastrol-induced β -catenin degradation was dependent on LKB1. (A) Western blot of LKB1 in SW480 and HCT116 cells, treated with or without Celastrol (0.75 μ M). β -actin was used as a loading control. (B) Immunohistochemistry staining of LKB1 in intestine tumor tissues of APC^{Min/+} mice and colon tumor tissues of AOM/DSS mice, treated with or without Celastrol (1 mg/kg), respectively. Wildtype C57 mice were used as control. AD: AOM/DSS mice. Scale bar: 50 μ m (upper), 30 μ m (bottom). (C) SW480 and HCT116 cells were transfected with control plasmid or LKB1-expressing plasmid for 24 h, and treated with or without Celastrol (0.75 μ M) for another 24 h, respectively. LKB1, β -catenin, Yes-associated protein (YAP), and phospho-YAP (S127) were detected and β -actin was used as a loading control. (D) Western blot of LKB1 and β -catenin in SW480, SW480/LKB1-KO, and HCT116, HCT116/LKB1-KO cells, treated with or without Celastrol (0.75 μ M) for 24 h. β -actin was used as a loading control. (E) SW480/LKB1-KO and HCT116/LKB1-KO cells were transfected with control plasmid or LKB1-expressing plasmid for 24 h, and treated with or without Celastrol (0.75 μ M) for another 24 h, respectively. LKB1 and β -catenin were detected and β -actin was used as a loading control.

HCT116 and SW480 cells, and observed that LKB1 upregulation enhanced β -catenin degradation and YAP phosphorylation that was related to YAP degradation (Figure 4C). We also used the CRISPR-Cas9 system to stably establish the LKB1-knockout SW480 and HCT116 cells. The resistant monoclonal cells were designated as SW480/LKB1-KO and HCT116/LKB1-KO, respectively. Results showed that LKB1 deficiency attenuated Celastrol-induced β -catenin degradation (Figure 4D), whereas recovery of LKB1 expression in SW480/LKB1-KO and HCT116/LKB1-KO cells significantly decreased β -catenin expression

(Figure 4E). These data implied that LKB1 was indispensable in promoting β -catenin degradation in CRC cells.

In addition to upregulating LKB1 protein expression, Celastrol also affected LKB1 transcriptional levels. LKB1 promoter contains a predicted HSF1 binding site (Figure 5A), implying that Celastrol may enhance LKB1 transcriptional activity *via* HSF1. We overexpressed HSF1 in SW480 and HCT116 cells, and detected increased LKB1 mRNAs (Figure 5B). ChIP assay identified HSF1 binding to the heat shock element (HSE) on LKB1 promoter (Figure 5C).




Figure 5. Celastrol increased the transcriptional activation of LKB1 partly through HSF1.

(A) Predicted HSF1 binding site in the LKB1 promoter region.

(B) Real-time polymerase chain reaction (PCR) of LKB1 in SW480 and HCT116 cells transfected with control plasmid or HSF1-expressing plasmid. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control. Values are mean \pm standard error of the mean (SEM) ($n = 3$). * $p < 0.05$.

(C) Chromatin immunoprecipitation (ChIP) analysis showed that HSF1 was associated with the LKB1 promoter in HCT116 cells.

(D) Immunohistochemistry staining of HSF-1 in intestine tumor tissues of APC^{Min/+} mice and in colon sections of AOM/DSS mice. Wildtype C57 mice were used as controls. AD: AOM/DSS mice. Scale bar: 50 μ m (upper), 30 μ m (bottom).

(E) SW480 and HCT116 cells were transfected with control plasmid or HSF1-expressing plasmid for 24 h, and treated with or without Celastrol (0.75 μ M) for another 24 h, respectively. HSF1, LKB1, AMPK α , pho-AMPK α (Thr172), β -catenin, Yes-associated protein (YAP), and pho-YAP(S127) were detected, and β -actin was used as a loading control.

(F) SW480 and HCT116 cells were transfected with scramble or HSF1-specific siRNA for 24 h, and treated with or without Celastrol (0.75 μ M) for another 24 h, respectively. HSF1, LKB1, AMPK α , pho-AMPK α (Thr172), β -catenin, YAP, and pho-YAP(S127) were detected and β -actin was used as a loading control.

Celastrol treatment induced HSF1 expression in SW480 and HCT116 cells (Figure 5E), and elevated HSF1 also increased both LKB1 protein expression and YAP phosphorylation (Figure 5D and E). In addition, siRNA-mediated HSF1 suppression resisted β -catenin degradation through downregulation of LKB1 and YAP phosphorylation (Figure 5F).

The energy sensor AMPK family proteins are the main downstream targets of LKB1,⁴¹ and AMPK also modulated YAP.⁴² Celastrol-induced HSF1 upregulation also increased AMPK α phosphorylation, whereas siRNA-mediated HSF1 attenuation downregulated AMPK α phosphorylation (Figure 5E and F). Furthermore, as shown in Figure 6A, LKB1 overexpression increased AMPK α phosphorylation, but did not change the total AMPK α protein levels. Celastrol treatment further induced AMPK α phosphorylation in both SW480 and HCT116 cells. Compound C (also known as Dorsomorphin 2HCl) is an effective and reversible AMPK selective inhibitor.⁴³ When Compound C was used to inhibit AMPK α expression, Celastrol-induced β -catenin and YAP degradation in SW480 and HCT116 cells were blocked as compared with the nontreated group, and LKB1 overexpression could partly counteract the effect (Figure 6B), which suggested that AMPK α partially promoted Celastrol-induced β -catenin and YAP degradation in LKB1-overexpressing SW480 and HCT116 cells. Moreover, IP was performed in SW480 and HCT116 cells treated with or without Celastrol. As shown in Figure 6C, Celastrol treatment enhanced the AMPK α and LKB1 complex formation and also increased YAP phosphorylation.

These above findings further elucidated the molecular mechanisms of Celastrol-induced β -catenin degradation, which at least partially *via* the HSF1-LKB1/AMPK α -YAP cascade.

LKB1 deficiency promoted CRC progression and attenuated the tumor inhibitory effect of Celastrol

To further investigate LKB1 roles in Celastrol-mediated inhibition of colorectal tumor growth, colony formation *in vitro* and xenograft growth assay *in vivo* were performed. As shown in Figure 7A and B, LKB1 depletion in SW480/LKB1-KO and HCT116/LKB1-KO cells resulted in increased colonies *in vitro* and increased tumor size *in vivo* as compared to the parental control

cells. Celastrol-mediated inhibition of colorectal cell growth *in vitro* and *in vivo* were attenuated by LKB1 depletion in SW480/LKB1-KO and HCT116/LKB1-KO cells compared with control groups, respectively. β -catenin downregulation and LKB1 upregulation were both detected in xenografts of SW480 and HCT116 cells with Celastrol treatment, as compared with nontreated control groups. However, β -catenin expression did not change in tumors derived from SW480/LKB1-KO and HCT116/LKB1-KO cells treated with or without Celastrol, and LKB1 expression was not detectable (Figure 7C).

To better understand the roles of LKB1 *in vivo*, intestinal-specific LKB1-KO ($Cre^+ LKB1^{+/loxP}$) mice were treated with AOM/DSS and received intraperitoneal injection of Celastrol (1mg/kg) or PBS controls for 3 weeks (three times/week). Compared with the control $Cre^- LKB1^{+/loxP}$ mice, $Cre^+ LKB1^{+/loxP}$ mice formed more tumors with the treatment of AOM/DSS. Interestingly, Celastrol-mediated tumor suppression was not effective in the $Cre^+ LKB1^{+/loxP}$ mice (Figure 7D). Immunohistochemistry results showed that β -catenin expression was upregulated in the colon of $Cre^+ LKB1^{+/loxP}$ mice, no matter whether treated or not treated with Celastrol. However, Celastrol treatment decreased β -catenin expression in the $Cre^+ LKB1^{+/loxP}$ mice (Figure 7E). These results verified the important role of LKB1 in Celastrol-mediated anti-CRC effect.

Discussion

Celastrol as an immunomodulator to suppress tumor necrosis factor (TNF)- α and interleukin (IL)-6 has been applied in clinical practice.⁴⁴ In recent years, the anticancer effects of Celastrol have been investigated in different cancer cell lines and animal models. Previous studies have indicated that Celastrol exerted synergistic effects with PHA-665752 and inhibited cell growth, migration and apoptosis of c-Met-deficient hepatocellular carcinoma both *in vitro* and *in vivo*,⁴⁵ which provided the therapeutic potential of Celastrol in cancer treatment. Moreira *et al.* indicated that Celastrol exhibited significant chemopreventive and chemosensitizing activities on doxorubicin-resistant colon cancer cells,⁴⁶ further hinting the role of Celastrol as a candidate for adjuvant medicine on the colon cancer. In the present study, our results showed that the intraperitoneal injection of Celastrol had significantly potent inhibition effect on spontaneous and




Figure 6. Celastrol-induced β -catenin degradation was partly mediated by activating the LKB1-AMPK α pathway.

(A) SW480 and HCT116 cells were transfected with control plasmid or LKB1-expressing plasmid for 24 h, and treated with or without Celastrol (0.75 μ M) for another 24 h, respectively. LKB1, AMPK α , pho-AMPK α (Thr172) were detected and β -actin was used as a loading control.

(B) SW480 and HCT116 cells were transfected with control plasmid or LKB1-expressing plasmid for 24 h, and then treated with or without Compound C (10 μ M) for 30 min, followed by Celastrol (0.75 μ M) treatment for another 24 h, respectively. LKB1, AMPK α , pho-AMPK α (Thr172), β -catenin, and Yes-associated protein (YAP) were detected by Western blot and β -actin was used as a loading control.

(C) SW480 and HCT116 cells were transfected with control plasmid or LKB1-expressing plasmid for 24 h, and treated with or without Celastrol (0.75 μ M) for another 24 h, respectively. Cell lysates were subjected to immunoprecipitation with LKB1 antibody followed by immunoblot with antibodies against LKB1, AMPK α , and pho-AMPK α (Thr172). Total lysates were used as input control.

carcinogen-induced colitis-associated CRC in mice, and the inhibitory efficiency of Celastrol is similar to 5-FU (Supplementary Figure S1B and C). Interestingly, another study indicated that dietary Celastrol supplementation also had the suppressive effect on CRC,⁴⁷ which further

suggested the potential for Celastrol as a clinical medication. To further understand the mechanism of Celastrol in inhibiting CRC growth would be beneficial for the therapeutic application of Celastrol. Bufu *et al.* indicated that Celastrol-induced anti-tumor effects were mediated




Figure 7. LKB1 deficiency promoted colorectal cancer progression and attenuated the tumor inhibitory effect of Celestrol.

(A) Colony formation of SW480 and SW480/LKB1-KO cells treated with or without Celestrol (0.75 μ M). Quantitative results were shown. The inhibition ratio of Celestrol was analyzed. Values are mean \pm standard error of the mean (SEM) ($n = 3$). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.
 (B) Representative images of xenograft tumors. Tumor weight were analyzed. Values are mean \pm SEM ($n = 4$). * $p < 0.05$, *** $p < 0.001$.
 (C) Expressions of β -catenin and LKB1 were detected in the xenograft tumors by immunohistochemistry. Scale bar: 50 μ m.

Figure 7. (Continued)

Figure 7. (Continued)

(D) Representative macroscopic images of colon and tumors. Tumor numbers of colon and were analyzed, respectively. Values are mean \pm SEM. *Cre-LKB1^{+loxp}* group: Control mice ($n = 7$), AOM/DSS mice ($n = 8$), and AOM/DSS mice treated with Celastrol (1mg/kg) ($n = 10$). *Cre⁺ LKB1^{+loxp}* group: Control mice ($n = 4$), AOM/DSS mice ($n = 8$), and AOM/DSS mice treated with Celastrol (1mg/kg) ($n = 11$). AD: AOM/DSS mice.

(E) Immunohistochemistry staining of β -catenin and LKB1 in colon tumor tissues of *Cre-LKB1^{+loxp}* mice and *Cre⁺ LKB1^{+loxp}* mice. Scale bar: 50 μ m (upper), 30 μ m (bottom).

(F) The mechanism of Celastrol inhibitory effect on colorectal cancer growth. Celastrol enhanced the transcriptional activity of LKB1 *via* increasing HSF1 expression, and then promoted the AMPK α and LKB1 complex formation, which led to the phosphorylation of Yes-associated protein (YAP) in the cytoplasm. Phosphorylated YAP existed in the destruction complex of β -catenin and promoted β -catenin degradation through the ubiquitin and proteasome system.

through MMP3 and MMP7 by the PI3K/AKT signaling pathway, which is crucial for CRC development and progression.⁴⁸ However, dys-regulated APC/ β -catenin signaling pathway is an early and generally accepted event in CRC tumorigenesis. Here, we demonstrated that Celastrol promoted β -catenin degradation *in vitro* and *in vivo*. Sustained activation of β -catenin facilitated colony formation of SW480 and HCT116 cells. Celastrol decreased β -catenin abundance in a dose- and time-dependent manner in SW480 and HCT116 cells (Figure 2A and Figure S2A), and also suppressed downstream genes of β -catenin, including *c-Myc*, *survivin*, *CYR61*, and *Cyclin D1*.

Downregulation of Hippo signaling is correlated with upregulation of Wnt/ β -catenin signaling in human CRCs. The tumor-derived stabilized form of β -catenin induced by the mutant APC was suppressed by activation of Hippo pathway.⁴⁰ YAP/TAZ act as downstream effectors of the alternative Wnt signaling pathway and mediate the biological functions including gene expression, osteogenic differentiation, cell migration, and antagonism of Wnt/ β -catenin signaling.⁴⁹ However, some studies indicated that YAP was essential for β -catenin nuclear accumulation in intestinal regeneration and survival of β -catenin-driven CRC.^{9,10} Here, we found that phosphorylated YAP was required in the process of Celastrol-induced β -catenin degradation. Phosphorylated YAP loses its activation by sequestering in the cytoplasm and is degraded through the ubiquitin–proteasome pathway.⁵⁰ YAP^{S127A} causes YAP accumulation from the cytoplasm into the nucleus without degradation. Our data showed that overexpressing the wildtype YAP intensified Celastrol-induced β -catenin degradation, whereas the nuclear-localized YAP^{S127A} prevented β -catenin degradation (Figure 3A). Recent studies pointed out that Ser397 of YAP could regulate the location of YAP in the

cytoplasm and nucleus^{51,52} and regulate YAP degradation. Our results also indicated that Celastrol and LKB1 overexpression could induced the phosphorylation at S397 site of YAP (data not shown). These may provide hints that the phosphorylation at S127 could cause YAP sequestering in the cytoplasm, which promoted the degradation of β -catenin through the destruction complex, however, the degradation of YAP may need other phosphorylated sites, such as S397.

In addition, our data proved that LKB1 played an important role in Celastrol-mediated inhibition of CRC growth. LKB1 is commonly known as a tumor suppressor gene because its hereditary mutation is responsible for Peutz–Jeghers syndrome,⁵³ and somatic inactivation of LKB1 is found in non-small cell lung cancer, melanoma, and cervical cancers.⁵⁴ Therapeutic strategies against LKB1-mutant cancer are emerging.⁵⁴ We showed that LKB1 deficiency promoted CRC cell growth and partially attenuated the inhibitory effect of Celastrol in tumor growth both *in vitro* and *in vivo*. Notably, the homozygous deletion of LKB1 (*Cre⁺ LKB1^{loxp/loxp}*) mice form more tumors in colon with the treatment of AOM/DSS than the *Cre⁺ LKB1^{+loxp}* mice, and Celastrol almost has no effect on the colon tumor growth in *Cre⁺ LKB1^{loxp/loxp}* mice (data not shown). AMPK α , the downstream effector of LKB1, also participated in the process of Celastrol-induced β -catenin degradation. Celastrol influenced the phosphorylation of AMPK, but not MAPK (data not shown). The inhibitor of AMPK partially inhibited Celastrol-induced β -catenin and YAP degradation, which further suggested the connection between LKB1, AMPK, and YAP.

Furthermore, intestinal inflammation is inseparable with colitis-associated cancer (CAC).⁵⁵ As a traditional herbal drug, Celastrol has been used to treat inflammatory disease such as allergic

asthma.¹⁹ The latest research showed that Celastrol results in appetite reduction (but not reduction in energy expenditure) and dramatic weight loss in hyperleptinemic diet-induced obese (DIO) mice by increasing leptin sensitivity, but not in mice that lack leptin action,⁵⁶ which demonstrated that Celastrol is a true leptin sensitizer.^{56,57} More interestingly, Lei Cao *et al.*⁵⁸ found that enriched environment (EE) could significantly reduce cancer burden in both a syngeneic melanoma as well as a colon cancer model through hypothalamic brain-derived neurotrophic factor (BDNF)/leptin axis *via* sympathoneural β -adrenergic signaling. All these experimental findings pointed out the relationship between the central nervous system (CNS) and cancer and suggested that Celastrol as a promising agent for the pharmacological treatment of colon cancer may have other mechanisms. More studies are needed to identify the mechanism of action of Celastrol.

There are some limitations in our study. First, our study showed that Celastrol-induced β -catenin degradation was dependent on the phosphorylation of YAP S127. Whether YAP phosphorylation at S127 site involved in Celastrol treatment and LKB1/AMPK signaling was essential for YAP degradation is worth to further investigated in future studies. Second, we fleshed out the molecule-to-molecule mechanism of Celastrol-induced β -catenin degradation in animal and cellular models. To expand the application of Celastrol as a preclinical cancer drug, we will need to further verify the effect of Celastrol in patient-derived xenograft (PDX) models of CRC.

In summary, our current study first revealed that Celastrol inhibited CRC cell growth *in vitro* and *in vivo* by promoting β -catenin degradation, through activating the LKB1-AMPK α pathway and phosphorylating YAP. Celastrol upregulated HSF1 expression, and HSF1 overexpression enhanced LKB1 transcriptional activity. Subsequently, LKB1 activated AMPK α and YAP, and promoted β -catenin degradation through the ubiquitin-proteasome system (Figure 7F). These observations elucidate the molecular mechanisms of the effect of Celastrol on CRC growth, and provide evidence in support of the potential application of Celastrol in CRC therapy.

Acknowledgements

The authors thank Professor Quan Chen for the parental T-Rex-293 cells.

Author contributions

Conception and design: Shuren Wang, Mei Liu, Ningzhi Xu.

Acquisition of data: Shuren Wang, Kai Ma, Yu Wang, Guanghui Hu.

Analysis and interpretation of data: Shuren Wang, Mei Liu.

Administrative, technical, or material support: Lechuang Chen, Zhuo Li, Cuiqi Zhou, Chenfei Hu, Qing Xu, Hongxia Zhu.

Project administration: Shuren Wang, Mei Liu, Ningzhi Xu.

Study supervision: Mei Liu, Ningzhi Xu.

Writing original draft: Shuren Wang.

Writing review and editing: Shuren Wang, Mei Liu, Ningzhi Xu, Cuiqi Zhou.

Funding

This work was supported by the National Key Research and Development (R&D) Program of China (grant numbers 2016YFC0906000, 2016YFC0906002, and 2016YFC1302103), National Natural Science Foundation (grant number 81321091), CAMS Innovation Fund for Medical Sciences (CIFMS) (grant number 2016-I2M-1-001), National Basic Research Program of China (grant number 2011CB910704), and Postgraduate Innovation Fund of the Beijing Union Medical College (grant number 2014-0710-1015), P. R. China. The funders had no role in study design, data collection and analysis, interpretation of data, or preparation of the manuscript.

Conflict of interest statement

The authors declare that there is no conflict of interest.

Supplemental material

Supplemental material for this article is available online.

ORCID iD

Mei Liu  <https://orcid.org/0000-0002-7364-6318>

References

1. Chen W, Zheng R, Baade PD, *et al.* Cancer statistics in China, 2015. *CA Cancer J Clin* 2016; 66: 115–132.
2. Markowitz SD and Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. *N Engl J Med* 2009; 361: 2449–2460.

3. Clevers H. Wnt/beta-catenin signaling in development and disease. *Cell* 2006; 127: 469–480.
4. Feng GS. Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. *Cancer Cell* 2012; 21: 150–154.
5. Azzolin L, Panciera T, Soligo S, *et al.* YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. *Cell* 2014; 158: 157–170.
6. Zhao B, Li L, Tumaneng K, *et al.* A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). *Genes Dev* 2010; 24: 72–85.
7. Cai J, Maitra A, Anders RA, *et al.* beta-Catenin destruction complex-independent regulation of Hippo-YAP signaling by APC in intestinal tumorigenesis. *Genes Dev* 2015; 29: 1493–1506.
8. Cai J, Zhang N, Zheng Y, *et al.* The Hippo signaling pathway restricts the oncogenic potential of an intestinal regeneration program. *Genes Dev* 2010; 24: 2383–2388.
9. Rosenbluh J, Nijhawan D, Cox AG, *et al.* Beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. *Cell* 2012; 151: 1457–1473.
10. Oudhoff MJ, Braam MJ, Freeman SA, *et al.* SETD7 controls intestinal regeneration and tumorigenesis by regulating Wnt/beta-Catenin and hippo/YAP signaling. *Dev Cell* 2016; 37: 47–57.
11. Barry ER, Morikawa T, Butler BL, *et al.* Restriction of intestinal stem cell expansion and the regenerative response by YAP. *Nature* 2013, 493: 106–110.
12. Gailite I, Aerne BL and Tapon N. Differential control of Yorkie activity by LKB1/AMPK and the Hippo/Warts cascade in the central nervous system. *Proc Natl Acad Sci USA* 2015; 112: E5169–E5178.
13. Sanchez-Cespedes M, Parrella P, Esteller M, *et al.* Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. *Cancer Res* 2002; 62: 3659–3662.
14. Guldborg P, thor Straten P, Ahrenkiel V, *et al.* Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. *Oncogene* 1999; 18: 1777–1780.
15. Nguyen HB, Babcock JT, Wells CD, *et al.* LKB1 tumor suppressor regulates AMP kinase/mTOR-independent cell growth and proliferation via the phosphorylation of Yap. *Oncogene* 2013; 32: 4100–4109.
16. Mohseni M, Sun J, Lau A, *et al.* A genetic screen identifies an LKB1-MARK signalling axis controlling the Hippo-YAP pathway. *Nat Cell Biol* 2014; 16: 108–117.
17. Gao Y, Zhang W, Han X, *et al.* YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression. *Nat Commun* 2014; 5: 4629.
18. Ma LG, Bian SB, Cui JX, *et al.* LKB1 inhibits the proliferation of gastric cancer cells by suppressing the nuclear translocation of Yap and beta-catenin. *Int J Mol Med* 2016; 37: 1039–1048.
19. Kannaiyan R, Shanmugam MK and Sethi G. Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. *Cancer Lett* 2011; 303: 9–20.
20. Liu Z, Ma L, Wen ZS, *et al.* Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. *Carcinogenesis* 2014; 35: 905–914.
21. Zhu H, Liu XW, Ding WJ, *et al.* Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L. *Cancer Lett* 2010; 297: 155–164.
22. Ge P, Ji X, Ding Y, *et al.* Celastrol causes apoptosis and cell cycle arrest in rat glioma cells. *Neurol Res* 2010; 32: 94–100.
23. Peng B, Xu L, Cao F, *et al.* HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way. *Mol Cancer* 2010; 9: 79.
24. Mezzanotte L, An N, Mol IM, *et al.* A New Multicolor Bioluminescence Imaging Platform to Investigate NF-kappa B Activity and Apoptosis in Human Breast Cancer Cells. *PLoS One* 2014; 9.
25. Yang HJ, Chen D, Cui QZC, *et al.* Celastrol, a triterpene extracted from the Chinese “Thunder of God Vine,” is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. *Cancer Res* 2006; 66: 4758–4765.
26. Ma X, Xu L, Alberobello AT, *et al.* Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1alpha transcriptional axis. *Cell Metab* 2015; 22: 695–708.
27. Morimoto RI. Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. *Genes Dev* 1998; 12: 3788–3796.
28. Anckar J and Sistonen L. Regulation of HSF1 function in the heat stress response: implications in aging and disease. *Annu Rev Biochem* 2011; 80: 1089–1115.

29. Shaker ME, Ashamalla SA and Houssen ME. Celastrol ameliorates murine colitis via modulating oxidative stress, inflammatory cytokines and intestinal homeostasis. *Chemi Biol Interact* 2014; 210: 26–33.
30. Lin L, Sun Y, Wang D, *et al.* Celastrol ameliorates ulcerative colitis-related colorectal cancer in Mice via suppressing inflammatory responses and epithelial–mesenchymal transition. *Front Pharmacol* 2015; 6: 320.
31. Lu W, Jia G, Meng X, *et al.* Beta-catenin mediates the apoptosis induction effect of celastrol in HT29 cells. *Life Sci* 2012; 91: 279–283.
32. Zhang W, Yan S, Liu M, *et al.* Beta-Catenin/TCF pathway plays a vital role in selenium induced-growth inhibition and apoptosis in esophageal squamous cell carcinoma (ESCC) cells. *Cancer Lett* 2010; 296: 113–122.
33. Ma K, Xu Q, Wang S, *et al.* Nuclear accumulation of Yes-Associated Protein (YAP) maintains the survival of doxorubicin-induced senescent cells by promoting survivin expression. *Cancer Lett* 2016; 375: 84–91.
34. Liu M, An J, Huang M, *et al.* MicroRNA-492 overexpression involves in cell proliferation, migration, and radiotherapy response of cervical squamous cell carcinomas. *Mol Carcinog* 2018; 57: 32–43.
35. Zhou C, Liu S, Zhou X, *et al.* Overexpression of human pituitary tumor transforming gene (hPTTG), is regulated by beta-catenin / TCF pathway in human esophageal squamous cell carcinoma. *Int J Cancer* 2005; 113: 891–898.
36. Wang S, Ma K, Chen L, *et al.* TAZ promotes cell growth and inhibits Celastrol-induced cell apoptosis. *Biosci Rep* 2016, 36: e00386.
37. Savari S, Chandrashekar NK, Osman J, *et al.* Cysteinyl leukotriene 1 receptor influences intestinal polyp incidence in a gender-specific manner in the ApcMin/+ mouse model. *Carcinogenesis* 2016; 37: 491–499.
38. Zhang W, Chen L, Ma K, *et al.* Polarization of macrophages in the tumor microenvironment is influenced by EGFR signaling within colon cancer cells. *Oncotarget* 2016, 7: 75366–75378.
39. Klymkowsky MW. Beta-catenin and its regulatory network. *Human Pathol* 2005; 36: 225–227.
40. Imajo M, Miyatake K, Iimura A, *et al.* A molecular mechanism that links Hippo signalling to the inhibition of Wnt/beta-catenin signalling. *Embo J* 2012; 31: 1109–1122.
41. Lizcano JM, Goransson O, Toth R, *et al.* LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. *EMBO J* 2004; 23: 833–843.
42. DeRan M, Yang J, Shen CH, *et al.* Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiotensin-like 1 protein. *Cell Rep* 2014; 9: 495–503.
43. Dorr JR, Yu Y, Milanovic M, *et al.* Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. *Nature* 2013; 501: 421–425.
44. Kim Y, Kim K, Lee H, *et al.* Celastrol binds to ERK and inhibits FcepsilonRI signaling to exert an anti-allergic effect. *Eur J Pharmacol* 2009; 612: 131–142.
45. Jiang HL, Jin JZ, Wu D, *et al.* Celastrol exerts synergistic effects with PHA-665752 and inhibits tumor growth of c-Met-deficient hepatocellular carcinoma in vivo. *Mol Biol Rep* 2013; 40: 4203–4209.
46. Moreira H, Szyjka A and Gasiorowski K. Chemopreventive activity of celastrol in drug-resistant human colon carcinoma cell cultures. *Oncotarget* 2018, 9: 21211–21223.
47. Barker EC, Kim BG, Yoon JH, *et al.* Potent suppression of both spontaneous and carcinogen-induced colitis-associated colorectal cancer in mice by dietary celastrol supplementation. *Carcinogenesis* 2018; 39: 36–46.
48. Bufu T, Di X, Yilin Z, *et al.* Celastrol inhibits colorectal cancer cell proliferation and migration through suppression of MMP3 and MMP7 by the PI3K/AKT signaling pathway. *Anticancer Drugs* 2018; 29: 530–538.
49. Park HW, Kim YC, Yu B, *et al.* Alternative Wnt signaling activates YAP/TAZ. *Cell* 2015; 162: 780–794.
50. Zhao B, Wei X, Li W, *et al.* Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. *Gene Dev* 2007; 21: 2747–2761.
51. Hu JK, Du W, Shelton SJ, *et al.* An FAK-YAP-mTOR signaling axis regulates stem cell-based tissue renewal in mice. *Cell Stem Cell* 2017; 21: 91–106.e106.
52. Qi Q, Li DY, Luo HR, *et al.* Netrin-1 exerts oncogenic activities through enhancing Yes-associated protein stability. *Proc Natl Acad Sci USA* 2015; 112: 7255–7260.

53. Hemminki A, Markie D, Tomlinson I, *et al.* A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. *Nature* 1998; 391: 184–187.
54. Zhou W, Zhang J and Marcus AI. LKB1 Tumor suppressor: therapeutic opportunities knock when LKB1 is inactivated. *Genes Dis* 2014; 1: 64–74.
55. Balkwill F and Mantovani A. Inflammation and cancer: back to Virchow? *Lancet* 2001; 357: 539–545.
56. Liu J, Lee J, Salazar Hernandez MA, *et al.* Treatment of obesity with celastrol. *Cell* 2015; 161: 999–1011.
57. Greenhill C. Celastrol identified as a leptin sensitizer and potential novel treatment for obesity. *Nat Rev Endocrinol* 2015; 11: 444.
58. Cao L, Liu X, Lin EJ, *et al.* Environmental and genetic activation of a brain-adipocyte BDNF/leptin axis causes cancer remission and inhibition. *Cell* 2010; 142: 52–64.

Visit SAGE journals online
[journals.sagepub.com/
home/tam](http://journals.sagepub.com/home/tam)

 SAGE journals